Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Recombinant proplatelet basic protein (PPBP), also known as CXCL7, is a recombinant form of the human chemokine belonging to the CXC family. PPBP is primarily derived from platelets and is a well-known mediator of leukocyte recruitment and activation. In the context of chronic inflammatory diseases such as psoriasis, PPBP has been identified as a critical molecular link between cutaneous inflammation and vascular pathology. Research indicates that PPBP exacerbates atherosclerosis by inducing mitochondrial dysfunction in aortic endothelial cells through the ZNG1F pathway. While PPBP is a naturally occurring protein, the recombinant version is utilized as a research tool to investigate the mechanistic pathways of atherogenesis and to evaluate the efficacy of potential therapeutic interventions, such as anti-PPBP neutralizing antibodies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on recombinant proplatelet basic protein.